Weekly Research Analysts’ Ratings Changes for Inozyme Pharma (INZY)

A number of firms have modified their ratings and price targets on shares of Inozyme Pharma (NASDAQ: INZY) recently:

• 11/6/2024 – Inozyme Pharma had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
• 11/6/2024 – Inozyme Pharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
• 11/5/2024 – Inozyme Pharma had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, down previously from $15.00.
• 10/25/2024 – Inozyme Pharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
• 10/25/2024 – Inozyme Pharma had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
• 9/30/2024 – Inozyme Pharma had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.

Inozyme Pharma Stock Performance

NASDAQ:INZY traded down $0.03 during midday trading on Thursday, reaching $3.52. The stock had a trading volume of 12,634 shares, compared to its average volume of 414,257. The firm’s fifty day simple moving average is $5.00 and its 200-day simple moving average is $4.91. Inozyme Pharma, Inc. has a 1-year low of $3.11 and a 1-year high of $7.80. The stock has a market capitalization of $226.12 million, a P/E ratio of -2.26 and a beta of 1.54. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68.

Inozyme Pharma (NASDAQ:INZY) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05. On average, equities research analysts forecast that Inozyme Pharma, Inc. will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Inozyme Pharma

A number of large investors have recently bought and sold shares of the company. Deerfield Management Company L.P. Series C bought a new stake in shares of Inozyme Pharma in the 2nd quarter valued at $52,000. Meeder Asset Management Inc. bought a new position in Inozyme Pharma during the second quarter valued at about $68,000. SG Americas Securities LLC bought a new stake in shares of Inozyme Pharma in the 3rd quarter worth approximately $81,000. Values First Advisors Inc. bought a new stake in shares of Inozyme Pharma in the second quarter valued at approximately $76,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Inozyme Pharma during the second quarter worth $84,000. 88.30% of the stock is currently owned by institutional investors and hedge funds.

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.